|
KMID : 0360319950270010084
|
|
Journal of Korean Cancer Research Association
1995 Volume.27 No. 1 p.84 ~ p.91
|
|
|
The Effect of Combination Chemotherapy with Mitomycin C, Vinblastine, and Cisplatin (MVP)in Patients with Advanced Non-Small Cell Lung Cancer
|
|
이상구
임영혁/이춘택/김형건/손태용/유영진/천은미/강윤구/김영환
|
|
|
Abstract
|
|
|
Objectives:
@EN Despite recent advances in chemotherapy, the treatment outcome of advanced non-small cell lung cancer(NSCLC) remains poor and NSCLC is still the predominant source of cancer-related mortality in worldwide. Thus, we evaluated the efficacy and
safety
of a combination chemotherapy with mitomycin C, vinblastine, and cisplatin(MVP) in advanced NSCLC patients in Korea
@ES Methods:
@EN Cisplatin was infused intravenously at a dose 20mg/m* from lst to5th day and mitomycin C 10mg/m* and vinblastine 6mg/m* were given intravenously on day 1. This treatment schedule was repeated every 3 weeks.
@ES Results:
@EN Among 94 evaluable patients, overall response rate was 44% of complete response. Squamous cell carcinoma responded better than adenocarcinoma. The median time to progression was 24 weeks and the median survival time was 42 weeks.
Statistically
significant survival advantage was observed in responder group(60 weeks vs. 36 weeks). The toxicities of this regimen were mild and well tolerated.
@ES Conclusion:
@EN In advanced NSCLC, MVP combination chemotherapy is relatively effective and safe.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|